

# Devitalization of Glioblastoma Cancer Cells by Non-invasive Physical Plasma: Modulation of Proliferative Signalling Cascades

SEBASTIAN LEHMANN<sup>1</sup>, SANDRA BIEN-MÖLLER<sup>1,2</sup>, SASCHA MARX<sup>3</sup>, SANDER BEKESCHUS<sup>4</sup>, HENRY W.S. SCHROEDER<sup>1</sup>, ALEXANDER MUSTEA<sup>5</sup> and MATTHIAS B. STOPE<sup>5</sup>

<sup>1</sup>Department of Neurosurgery, University Medicine Greifswald, Greifswald, Germany;

<sup>2</sup>Department of Pharmacology, University Medicine Greifswald, Greifswald, Germany;

<sup>3</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, U.S.A.;

<sup>4</sup>ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany;

<sup>5</sup>Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Bonn, Germany

**Abstract.** *Background/Aim:* Glioblastoma (GBM) is the most common and most lethal type of cancer of the central nervous system in adults. Despite aggressive treatment, which is based on surgical resection, if possible, followed by radiation and chemotherapy, a high recurrence rate and therapy resistance is observed. Thus, additional innovative therapies are urgently needed to improve the poor median survival of only 15 months. Treatment of solid tumours with non-invasive physical plasma (NIPP) represents such a novel and innovative anticancer procedure. *Materials and Methods:* In this study, we investigated the effect of NIPP, an ionized argon gas, on the *in vitro* growth of human GBM cell lines, LN-18 and U-87 MG. Proliferation was measured by live cell count. Subsequently, proliferative factors were analysed at the level of nucleic acids (polymerase chain reaction) and proteins (western blotting). *Results:* For both GBM lines, a treatment time-dependent decrease in growth was observed compared to controls. Additionally, NIPP treatment resulted in reduced rates of AKT serine/threonine kinase 1 (AKT1) and extracellular-regulated kinase 1/2 ERK1/2 expression, whereas expression of p21, proliferating cell nuclear antigen, and heat-shock proteins 90 $\alpha$  and 90 $\beta$  was not affected. In both cell lines, a strong increase in expression of tumour-

suppressive microRNA-1 (miR-1) was detected after exposure to NIPP. *Conclusion:* Our results demonstrated that NIPP is able to efficiently attenuate growth of GBM cells and suggest AKT1, ERK1/2 and miR-1 to be pivotal factors of NIPP-modulated cellular signalling. Translated into the clinical setting, NIPP may represent a promising option for the treatment of GBM.

Glioblastoma (GBM) represents the most aggressive brain tumour of glial origin and accounts for approximately 60% of all brain-derived tumours. The invasive and nearly always lethal phenotype of GBM is particularly characterized by behaviour of rapid and infiltrative growth deep into the healthy brain tissue (1-3). Despite multimodal therapy consisting of surgical resection followed by chemotherapy and radiation, the median survival is still only about 15 months. In spite of the investigation of new GBM treatment approaches, no substantial improvement in GBM therapy has been achieved in recent years (4, 5).

A promising and novel therapy option is the treatment of tumours with non-invasive physical plasma (NIPP), previously also known as cold atmospheric (pressure) plasma, which primarily consists of an ionized gas. Unlike classical thermal plasma, the fourth state of matter, NIPP is not in a thermal equilibrium, the ions in the gas cloud have a much lower kinetic energy than the ions in classical thermal plasma. This makes it possible to generate the plasma at room temperature (6). NIPP is generated by high-frequency, high-voltage discharges between two electrodes. The high energy input ionizes the gas passing the electrodes and NIPP is formed (6). Currently, there are two main techniques used to generate NIPP. In the plasma jet principle, a gas, usually a noble gas, is ionized between two electrodes and emerges as NIPP effluent. In dielectric barrier discharge, on the other hand, the ambient atmosphere between the electrode and the grounded surface to be treated is used to form a NIPP (6-8).

*Correspondence to:* Matthias Stope, Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany. Tel.: +49 22828711361, Fax: +49 22828716091, e-mail: matthias.stope@ukbonn.de

*Key Words:* Cold atmospheric plasma, cold atmosphere pressure plasma, tissue tolerable plasma, microRNA-1, AKT1.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>).

According to the current understanding, the effect of NIPP is based primarily on the formation of reactive oxygen species (ROS) which interact with cellular structures (9). ROS are formed at the interface of plasma and ambient atmosphere. In tissue, ROS lead to the induction of oxidative stress in the extracellular matrix, as well as in intracellular compartments. Due to the application of NIPP, modifications of the extracellular matrix, the cell membrane, and intracellular components and structures are observed. In particular, changes in cytoplasmic membrane permeability and induction of DNA double-strand breaks have been detected (9, 10). Thereby, dose-dependent effects of NIPP have been described for some time. At low doses, proliferative and pro-angiogenic actions of NIPP have been demonstrated (10). At high doses, cell damage resulting in apoptosis and necrosis was found. In this regard, not only were antimicrobial effects detected, but also a strong selectivity of NIPP in impairing the growth of tumour cells was shown (6, 8, 9). A large number of potential applications of NIPP are currently in clinical and pre-clinical investigation. At present, most advanced is the research regarding the application of NIPP for the treatment of acute and chronic wounds. Other possible areas of application which are currently under research include dentistry, ophthalmology, and the large field of oncology (8, 9, 11).

Although some studies have investigated the effects of NIPP on GBM, the underlying molecular mechanisms are still poorly understood. We therefore evaluated the effect of NIPP treatment on an *in vitro* GBM model, consisting of the well-established cell lines LN-18 and U-87 MG. Molecular analyses included of growth and resistance-associated proteins serine/threonine kinase 1 (AKT1), p44/p42 mitogen-activated protein kinase (ERK1/2), cyclin-dependent kinase inhibitor 1 (p21), proliferating cell nuclear antigen (PCNA), heat-shock protein 90 (HSP90) and microRNA-1 (*miR-1*).

## Materials and Methods

**Cell culture and NIPP treatment.** The maintenance of LN-18 and U-87 MG cells (both human GBM cell lines authenticated by the American Type Culture Collection, Manassas, VA, USA) was performed in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum, 2 mM glutamine and 1% non essential amino acid solution (100×) (all from PAN Laboratories, Cölbe, Germany) at 37°C with 95% humidity and 5% CO<sub>2</sub>.

For NIPP treatment, we used a Kinpen 09, a plasma jet manufactured by Neoplas tools (Greifswald, Germany). This physical plasma jet is operated with argon as carrier gas at a flow rate of 3 l/min. It creates a 9-13 mm long plasma effluent with a temperature below 42°C, and the sinusoidal operating frequency is approximately 1 MHz (12).

For cell growth experiments, 15,000 cells/well were seeded into a 24-well cell culture plate. In the experimental group, treatment with NIPP was performed for 5 s or 15 s. The control group was treated with non-ionized argon for the same time period. The

treatment of cells with the Kinpen 09 jet was performed manually. The jet was placed at a distance of 9-13 mm above the cell suspension such that the tip of the effluent only reached the surface of the cell culture medium. Subsequently, the cells were transferred into new 24-well plates in order to exclude a possible influence of NIPP on the surface of the primarily used cell culture plate. Cell growth was determined after 4, 24, 48, 72, 96, and 120 h of incubation using a CASY TT cell counter and analyser (Roche Applied Science, Mannheim, Germany) with a 150 µm capillary, after detaching the cells with trypsin. The measurement was performed three times with 400 µl each in triplicate.

**Western blotting.** For analysis of the expression and phosphorylation of selected proliferation-related proteins (AKT1, ERK1/2, HSP90α, HSP90β, p21, and PCNA), the treatment time with NIPP was set to 15 s. Measurement of target proteins was performed after 24 and 48 h of incubation. For preparation of protein lysates, harvested cells were incubated on ice for 30 min with lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 1 mM leupeptin, 1 mM aprotinin and 250 µg/ml sodium vanadate). BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA) was used to determine protein concentration of cell lysates. After protein denaturation in sodium dodecyl sulphate (SDS) sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue, 5% 2-mercaptoethanol) at 95°C for 5 min, 30 µg of each protein sample were separated on an SDS polyacrylamide gel. For immunoblotting a tank blot system (Bio-Rad, Hemphstead, UK) was used to transfer separated proteins onto a nitrocellulose membrane (GE Healthcare Life Science, Solingen, Germany). After blotting, membranes were blocked in 5% fetal bovine serum in Tris-buffered saline containing 0.05% Tween 20 (TBST) and 1% bovine serum albumin for 1 h at room temperature. For immunodetection, membranes were incubated with the primary antibodies (Table I) overnight at 4°C followed by a washing procedure with TBST. Incubation with the secondary antibodies was performed for one hour at room temperature again followed by washing step with TBST. For detection of chemiluminescent signals of horseradish peroxidase-coupled secondary antibodies, ChemiDoc XRS Imaging System (Bio-Rad) using ECL Plus Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA) followed by densitometric analysis (Quantity One; Bio-Rad) was used. Fluorescence signals of IRDye-conjugated secondary antibodies were detected using an Odyssey CLx Imaging System (Li-cor Bioscience, Bad Homburg, Germany). The relative chemiluminescence or fluorescence intensities of the specific bands were calculated and normalized to those of glyceraldehyde 3-phosphate dehydrogenase as a loading control.

**Quantitative reverse transcription-polymerase chain reaction (RT-PCR).** RT-PCR was used for quantification of *miR-1* expression after treatment of GBM cells with NIPP for 15 s, followed by a cell culture period of 24 and 48 h. For RNA isolation by phase segregation, peqGOLD TriFast (Peqlab, Erlangen, Germany) was used according to the manufacturer's protocol. Total RNA was determined by NanoDrop 2000 spectrometer (Peqlab), and samples were adjusted to a content of 100 ng RNA/µl. Synthesis of cDNA coding for *miR-1* and the housekeeping gene *U6* was achieved by a Thermal Cycler T3000 (Biometra, Göttingen, Germany) performing stem-loop RT-PCR with primers targeting specifically *miR-1* and *U6* (*miR-1* SLOOP, *U6* SLOOP, Table II).

Table I. Antibodies for western blot analysis.

Antibody target	Species	Manufacturer
p21	Rabbit	Abcam, Milton, England, UK
p44/42 mitogen-activated protein kinase/extracellular-regulated kinase 1/2	Rabbit	Cell Signaling Technology, Leiden, the Netherlands
Phospho-extracellular-regulated kinase 1/2	Rabbit	Cell Signaling Technology, Leiden, the Netherlands
Proliferating cell nuclear antigen	Rabbit	Santa Cruz Biotechnology, Heidelberg, Germany
AKT serine/threonine kinase 1	Rabbit	Cell Signaling Technology, Leiden, the Netherlands
Phospho-AKT serine/threonine kinase 1	Rabbit	Cell Signaling Technology, Leiden, the Netherlands
Glyceraldehyde 3-phosphate dehydrogenase	Mouse	Meridian Live Science, Memphis, TN, USA
Rabbit-horseradish peroxidase	Goat	Bio-Rad, München, Germany
Mouse-horseradish peroxidase	Goat	Bio-Rad, München, Germany
Mouse IRDye 800	Goat	LI-COR Biotechnology, Lincoln, NE, USA

Table II. Oligonucleotides for quantitative reverse transcription-polymerase chain reaction analysis.

Name	Sequence (5' -> 3')
<i>miR-1</i> SLOOP	GTCGTATCCAGTGCAGGGTCCGAGGTATCCGCACTGGATACGACATACAT
<i>miR-1</i> Forward	GCCCCGTGGAATGTAAAGAAGTATG
Universal reverse	GTGCAGGGTCCGAGGT
<i>U6</i> SLOOP	GTCATCCTTGCGCAGG
<i>U6</i> Forward	CGCTTCGGCAGCACATATAC
<i>U6</i> Reverse	AGGGCCATGCTAATCTTCT

Nucleic acid quantification was performed by real-time PCR with a CFX96 Real-Time PCR Detection System (Bio-Rad). Amplification of *miR-1* and *U6*-coding cDNA was achieved using specific forward- and reverse primers. Simultaneous fluorescence-based quantification was performed *via* SYBR-Green detection using SensiMix SYBR Hi-ROX Kit (Bioline, Luckenwalde, Germany) between the amplification cycles. The analysis of the quantitative PCR data was performed in CFX Manager 2.0 (Bio-Rad).

**Statistics.** Statistical analysis and graphical representation were performed using GraphPad Prism software 5.0 (GraphPad Software, Inc., San Diego CA, USA). Analysis of variance served as the test procedure for cell kinetics, and the Wilcoxon signed-rank test was used for analyses of western blot and RT-PCR data. A value of  $p < 0.05$  was considered to be statistically significant. Grubbs' test for identification of outliers was performed using GraphPad QQuickCalcs Outlier calculator.

## Results

**Dose- and time-dependent growth-inhibitory effect of NIPP on GBM cells.** In our study, we first evaluated the effect of NIPP on GBM cell proliferation by performing growth kinetics based on the measurement of living cells at 4, 24, 48, 72, 96 and 120 h after NIPP treatment. Both NIPP treatment durations led to a significant reduction in growth rate compared to the control group in U-87 MG cells

(Figure 1A), as well as in LN-18 cells (Figure 1B). This growth-inhibitory effect was most pronounced after 72, 96 and 120 h. In addition, there was a clear increase in growth inhibition when the duration of NIPP treatment was increased from 5 to 15 s. This observation was consistent and similar in both GBM cell lines. The LN-18 growth kinetics showed 48% less cell growth after 5 s of treatment, while after 15 s of treatment, a decrease of 87% was observed. The results for U-87 MG matched these findings, with growth rate reductions of 44% and 69%, respectively.

**Reduction of the AKT1 and ERK1/2 protein expression after NIPP treatment.** To evaluate which signalling pathways might be affected by NIPP treatment, we analysed the expression and phospho-activation of two proliferation-related kinases: AKT1 and ERK1/2 (13, 14). Figure 2 represents the expression and activation data of both AKT1 and ERK1/2 in U-87 MG (Figure 2A) and LN-18 (Figure 2B) cells.

U-87 MG cells showed a significant decrease (by half) in the expression of total AKT1 24 h after treatment with NIPP (Figure 2A). At the same time, the amount of phosphorylated, active AKT1 (*p*-AKT) was significantly increased (1.83-fold) by NIPP treatment (Figure 2B). However, 48 h after NIPP treatment, the relative levels of




Figure 1. Comparison of the effects of non-invasive physical plasma (NIPP) on cell growth of U-87 MG (A, B) and LN-18 (C, D) cells. Cells were treated for 5 (A, C) or 15 s (B, D) with NIPP or the carrier gas (argon; control). Living cells were assessed applying a CASY Cell Counter and Analyzer (OLS, Bremen, Germany) at 4, 24, 48, 72, 96, and 120 h after treatment. Data are given as mean and standard deviation (U-87 MG n=6, LN-18 n=5), two-way ANOVA with Bonferroni post-hoc test. Significantly different at:  $p < 0.05$ ;  $**p \leq 0.01$ ;  $***p \leq 0.001$ .

both activated and total AKT1 had returned to normal in U-87 MG cells. A similar pattern was observed for total ERK1/2 and its phosphorylated form (p-ERK1/2), with reduction of total ERK expression to 0.68 and a 2.77-fold increase in active p-ERK1/2 24 h after NIPP treatment of U-87 MG cells (Figure 2A), but this was not statistically significant ( $p=0.0625$ ).

In LN-18 cells, on the other hand, there was a slight (1.5- to 2.0-fold) but not significant increase in both the total and active AKT1 level after NIPP treatment. The total ERK1/2 expression was not significantly changed by NIPP but p-ERK1/2 was slightly reduced to 0.78 48 h after NIPP treatment of LN-18 cells (Figure 2B).

Expression of HSP90 $\alpha$ , HSP90 $\beta$ , p21, and PCNA is not affected after NIPP treatment. Since it is well-known that HSP90 promotes GBM cell viability by interaction with a wide range of client proteins to influence growth, survival, and the cell cycle (15), we next analysed HSP90 $\alpha$  and HSP90 $\beta$  expression at 24 and 48 h after NIPP treatment. As shown in Figure 3, in both U-87 MG (Figure 3A) and LN-18 (Figure 3B) cells, no significant change in either HSP90 $\alpha$  or HSP90 $\beta$  expression was detectable. Furthermore, protein expression of p21 and PCNA was also not significantly changed, despite a trend for a reduced PCNA content in U-87 MG cells 48 h after NIPP treatment.




Figure 2. Western blot analyses of total (t-) and phosphorylated (p-) forms of serine/threonine kinase 1 (AKT1) and extracellular-regulated kinase 1/2 (ERK1/2) in U-87 MG (A) and LN-18 (B) glioblastoma cells. Cells were treated for 15 s with non-invasive physical plasma (NIPP) or carrier gas (argon); control and protein expression was determined 24 and 48 h after NIPP treatment. Expression of t-AKT1 and t-ERK1/2 was normalized to the level of the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH). p-AKT1 and p-ERK1/2 were normalized to the content of t-AKT1 and t-ERK1/2, respectively. The upper panels show representative blots in each case; the lower panels present the statistical analyses of 4-8 independent experiments as the mean (relative to that of control cells) and standard deviation. Significantly different at: \* $p < 0.05$  and \*\* $p \leq 0.01$  by Wilcoxon signed-rank test.




Figure 3. Western blot analyses of heat-shock protein 90 $\alpha$  (HSP90 $\alpha$ ), HSP90 $\beta$ , p21, and proliferating cell nuclear antigen (PCNA) in U-87 MG (A) and LN-18 (B) glioblastoma cells. Cells were treated for 15 s with non-invasive physical plasma (NIPP) or carrier gas (argon; control) and protein expression was determined 24 and 48 h after NIPP treatment. Expression of proteins was normalized to the level of the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The upper panels show representative blots in each case; the lower panels present the statistical analyses of 4-8 independent experiments as the mean (relative to that of control cells) and standard deviation. There were no significant differences by Wilcoxon signed-rank test.




Figure 4. Expression of *miR-1* in U-87 MG (left) and LN-18 (right) glioblastoma cells. Cells were treated for 15 s with non-invasive physical plasma (NIPP) or carrier gas (argon; control) and *miR-1* expression was determined 24 and 48 h after NIPP treatment using quantitative reverse transcription-polymerase chain reaction analysis. *miR-1* expression was normalized to that of endogenously expressed U6 *snRNA*. Data are given as the mean and standard deviation ( $n=5-7$ ). \*Significantly different at  $p<0.05$  by Wilcoxon signed-rank test.

Expression of tumour-suppressive *miR-1* is elevated after NIPP treatment. An additional regulator of tumour progression is the tumour suppressor *miR-1*. As shown in Figure 4, 24 h after NIPP treatment a significant, almost 15-fold increase of the *miR-1* level in U-87 MG cells and a more than 5-fold up-regulation in LN-18 cells was observed. Interestingly, 48 h after NIPP treatment, a decrease of the *miR-1* content to the level of the controls was detectable in both GBM cell lines (Figure 4).

## Discussion

GBM is one of the most deadly and difficult-to-treat brain cancers because of its infiltrative growth behaviour. Complete tumour removal by surgery is nearly impossible. Due to therapy resistance, patients with GBM experience relapse within a few months, resulting in a short median overall survival of only about 15 months. This emphasizes the urgent need for novel GBM therapies. NIPP has emerged as potential and innovative anti-tumoural option for solid tumours.

NIPP has been investigated for its suitability in several applications, including the treatment of cancer (16, 17). The treatment of cancer has diversified with the use of NIPP, which was shown to induce apoptosis in many types of cancers, including melanoma, pancreatic, ovarian, breast cancer or lung cancer (18-22). Some studies evaluating the tumour-suppressive effect of NIPP on GBM cells also exist (23-26), however, the influence of NIPP on the regulation of intracellular signalling cascades and growth-regulatory

proteins is poorly understood. In *in vitro* experiments, an increased ROS content, intracellularly and extracellularly, as well as a restoration of sensitivity of *O*<sup>6</sup>-methyl-guanine DNA methyltransferase-positive tumour cells to temozolomide was demonstrated (6, 27, 28). More importantly, the first *in vivo* study also showed a significant reduction in growth of GBM in mice when treated with NIPP (26).

In this study, we investigated the influence of NIPP treatment on growth of two human GBM cell lines, LN-18 and U-87 MG. Additionally, we analysed the expression of key intracellular factors (AKT1, ERK1/2, HSP90 $\alpha$ , HSP90 $\beta$ , p21, PCNA and *miR-1*) which are known to be relevant for GBM growth and progression.

In our study, we demonstrated a significant growth-inhibitory effect of NIPP on GBM cell models. Such an anti-tumoural impact of NIPP was already described in the literature using different GBM cell lines and affirms the potential application of NIPP as a therapeutic option for treatment of patients with GBM (23-25, 28, 29). As partly shown by others, we also confirm the dose- and time-dependent effects of NIPP treatment. The earliest significant reductions in cell number were found 72 h after NIPP application to LN-18 and U-87 MG cells, an effect which was much stronger after 96 and 120 h of incubation. Additionally, treatment of GBM cells for 15 s was more effective than that for 5 s. The strong growth-inhibitory effects of NIPP treatment were associated with a regulation of signalling molecules relevant for tumour growth and progression which will be discussed in detail below.

NIPP-induced growth suppression was accompanied by a significant change in the regulation of the pro-oncogenic survival kinase AKT1, which is an effector kinase of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-AKT pathway. Strong evidence has revealed that AKT1 also plays a major role in GBM progression and aggressiveness (30). AKT1 is a key protein associated with anti-apoptotic processes, proliferation, and migration (31). In many tumour types, including GBM, AKT1 expression has been found to be elevated during progression. Thus, AKT1 is discussed as a crucial factor in tumourigenesis (13). We found a decrease in total AKT1 expression in U-87 MG cells 24 h after NIPP treatment. Due to its important role in cell survival, this reduction of AKT1 expression may be directly caused by NIPP-mediated cytotoxic effects. But unexpectedly, the amount of phosphorylated, active AKT1 was increased 24 h after NIPP treatment. Whether this was actually an increase in the activity of AKT1 or only a relative excess due to the reduced total AKT1 content cannot be answered by our experiments. Furthermore, 48 h after NIPP treatment, the levels of both total and *p*-AKT1 returned to those of the control. This may mean that NIPP causes a short-term change in regulation of AKT1 which might be sufficient to induce other growth-regulatory cascades. The temporary increase in active AKT1 protein might also represent a rapidly activated survival cascade to protect GBM cells from death, which then cannot be maintained due to further cell damage processes caused by NIPP. Interestingly, in LN-18 cells, no significant change in expression of AKT1 by NIPP was found in our study, but there was a trend for increased total and active AKT1. Discrepancies between LN-18 and U-87 MG cells might be based on the different status of phosphatase and tensin homologue (*PTEN*), which is negatively regulates the activation of AKT1 (32). While LN-18 express wild-type *PTEN*, U-87 MG cells are described as *PTEN*-negative, which might be the reason for the observed significant increase in active AKT1 in U-87 MG caused by the lack of *PTEN*-mediated inactivation of AKT1 (33). At later time points, it is conceivable that other factors control AKT1 activation such as integrin-linked kinase, which has been shown to regulate AKT1 activity in *PTEN*-mutant GBM cells (34, 35). Regulation of AKT1 by NIPP is not described in the literature, but oxidative stress, which is thought to be induced by NIPP, was shown to inactivate PI3K/AKT1 signalling, while activity of its negative regulator *PTEN* appears not to be regulated directly (36, 37).

Besides AKT1, a role of ERK1/2 in GBM pathogenesis is discussed (38). A trend for a similar pattern of regulation was found for ERK1/2, which also belongs to the survival kinases, in U-87 MG cells. Again, there was a slight down-regulation of total ERK1/2 protein but an enhanced level of ERK1/2 phosphorylation 24 h after NIPP treatment. An increase in ERK1/2 phospho-activation has been already

shown after treatment of melanoma cells and myeloblasts with NIPP (39, 40). In contrast, reduced total and active ERK1/2 were found in NIPP-treated prostate cancer cells (41). Thus, modulation of ERK1/2 by NIPP seems to be cell type-dependent. As a component of the RAS-ERK signalling cascade, ERK1/2 is an oncogenic kinase capable of influencing a variety of effectors, which are particularly associated with anti-apoptotic processes, cell growth and tumour progression (42, 43). Thus, an increased short-term activation of ERK1/2 by NIPP may represent a mode of protection for GBM cells to escape cell death as described for AKT1 above, which, however, cannot be maintained by additional cellular stress processes. Again, the observed changes of ERK1/2 in U-87 MG cells were not found in LN-18 cells. In contrast, there was a slight, but significant reduction in the level of *p*-ERK1/2 in LN-18 cells at 48 h after NIPP treatment. Once more, the different *PTEN* status of U-87 MG (*PTEN*-mutant) and LN-18 (*PTEN* wild-type) might be responsible for the different response of these two GBM cells to NIPP. Intact *PTEN*, described for LN-18 cells, is able to reduce ERK1/2 activation through inhibition of RAS, which can counteract the activation of ERK1/2 in LN-18 cells (44). In *PTEN*-mutant U-87 MG cells, there is no inhibition of RAS and thus also not of ERK1/2, which may conceivably lead to a greater increase in ERK1/2 activity.

Both the PI3K/AKT1 and mitogen-activated protein kinase/ERK1/2 pathways, as prominent drivers of GBM cell proliferation, are strongly dependent on HSP90 protein (15). Under chemotherapy, HSP90 promotes GBM cell viability and stabilizes inhibitors of apoptotic mechanisms. Thus, HSP90 contributes to chemoresistance (45, 46). Generally, HSP90 is considered a molecular chaperone responsible for correct folding, stabilization, and transport of proteins (47, 48). Two HSP90 isoforms are mainly expressed: the stress-induced HSP90 $\alpha$  and the constitutively expressed HSP90 $\beta$  type (47). In many tumours, including GBM, expression of HSP90 was observed to be elevated (45, 49). Numerous studies have demonstrated that inhibition of HSP90 reduces the growth of GBM cells (50, 51). However, tumour-selective cleavage of HSP90 by oxidative stress and NIPP have also been reported (52, 53), but no data exist on GBM regarding regulation of HSP90 by NIPP or oxidative stress as far as we are aware. In our study, no significant changes of HSP90 isoforms  $\alpha$  and  $\beta$  were detected in LN-18 and U-87 MG cells after NIPP application. Thus, HSP90 appears not to be a target of NIPP-mediated growth-inhibitory effects in GBM cells.

Both apoptosis and cell-cycle arrest are found to be induced by NIPP in tumour cells (54, 55). Expression analyses of the apoptosis-related and cell cycle-modulating proteins p21 and PCNA, which are also significantly involved in DNA replication and DNA repair, also showed no significant changes after NIPP application in both LN-18 and U-87 MG cells (56, 57). Due to the growth-inhibitory

effects of NIPP, a change in expression of the cell-cycle regulator p21 after NIPP treatment would have been conceivable. In contrast to our results, melanoma, colorectal and prostate cancer cells treated with NIPP demonstrated a significant modulation of p21 (41, 58). This argues for a cell type-dependent regulation of p21 expression after NIPP exposure and may link to p21-independent growth inhibition in GBM cells. Regarding PCNA, a cell type-specific regulation was found after NIPP treatment. Whereas an increase of PCNA expression was described in human gingival and osteoblast-like cells (59, 60), modulation of PCNA was lacking in squamous cell carcinoma and malignant melanoma cells (61). In line with these findings, analysis of PCNA expression in our study also revealed a lack of change in PCNA expression after NIPP treatment of GBM cells. PCNA is responsible for a fast and smooth process of DNA synthesis and the initiation of DNA repair processes (59). There is currently much discussion whether NIPP-induced ROS directly cause DNA damage or only induce apoptosis or other forms of cell death (62).

miRs play pivotal roles in tumourigenesis, apoptosis, and drug resistance in cancer cells due to their regulatory function in post-transcriptional gene expression (62). Among them, the tumour-suppressive *miR-1* has been shown to be predominantly down-regulated in almost all human cancer types, including GBM (62, 63). *miR-1* suppresses the expression of factors that promote cell growth and angiogenesis and suppress apoptosis (64). To the best of our knowledge, this is the first study to demonstrate a strong increase of *miR-1* after NIPP application in both LN-18 and U-87 MG cells. Thus, *miR-1* up-regulation may represent a molecular mediator responsible for the tumour-suppressive effects of NIPP. Remarkably, the increase in *miR-1* expression was only temporary and expression returned to the control level after 48 h of incubation, however, this short-term induction in *miR-1* expression might be sufficient for the subsequent signal cascades to inhibit cell growth. Moreover, *miR-1* has been classified as having a high potential to inhibit tumour progression and therapy resistance (65). Recently, Bronisz and colleagues showed that ectopic expression of *miR-1* in GBM cells inhibited cell growth, neovascularisation, and invasiveness *in vivo* (63). *miR-1* seems to have an important role as an effector molecule for inhibition of the aggressive growth behaviour of tumour cells such as GBM.

## Conclusion

NIPP represents a new and promising treatment option for therapy of a variety of tumours, including GBM. Although most studies are still in the experimental stage, there are initial studies that demonstrate benefits of its application in patients. Nevertheless, there still seems to be a long way to go before clinical NIPP application can find its way into

routine oncological therapy. Of note, a challenging part of treating GBM is that it is present in the brain, and any damage to the tissue during surgery or other treatment can cause a series of devastating effects in the central nervous system. Thus, the non-invasive set-up of NIPP, as suggested by Soni and colleagues (67), would be an important improvement for therapeutic options.

To date, many of the intracellular processes induced by NIPP in tumour cells have not been adequately studied or understood. Our study argues for a possible role of kinases, and especially of *miR-1*, as potential effectors of the growth-inhibitory effect of NIPP. This should be the subject of further research to improve the extremely poor survival of patients with GBM.

## Conflicts of Interest

The Authors declare that they have no competing interests.

## Authors' Contributions

Conceptualization, S.B.M., M.B.S., S.L.; methodology, S.L., S.M., S.B.; formal analysis, S.L., S.B.M., S.B. and M.B.S.; investigation, S.L., S.B.M., S.M., S.B. and M.B.S.; writing - original draft preparation, S.L., S.B.M., H.W.S.S., A.M. and M.B.S.; writing - review and editing, S.L., S.B.M., H.W.S.S., A.M. and M.B.S.; visualization, S.L., S.B.M. and M.B.S.; supervision S.B.M. and M.B.S.

## Acknowledgements

The Authors thank Lena Zeyda for her dedicated experimental support and Christian Scharf for his interested guidance of the NIPP experiments.

## References

- 1 Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B and Faul C: A clinical review of treatment outcomes in glioblastoma multiforme – the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? *Br J Radiol* 85(1017): e729-e733, 2012. PMID: 22215883. DOI: 10.1259/bjr/83796755
- 2 Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM and Stupp R: Newly diagnosed glioblastoma: a review on clinical management. *Oncology (Williston Park)* 33(3): 91-100, 2019. PMID: 30866031.
- 3 Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT and Zadeh G: Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. *Arch Immunol Ther Exp (Warsz)* 61(1): 25-41, 2013. PMID: 23224339. DOI: 10.1007/s00005-012-0203-0
- 4 Taylor OG, Brzozowski JS and Skelding KA: Glioblastoma multiforme: an overview of emerging therapeutic targets. *Front Oncol* 9: 963, 2019. PMID: 31616641. DOI: 10.3389/fonc.2019.00963
- 5 Bianco J, Bastiancich C, Jankovski A, des Rieux A, Pr at V and Danhier F: On glioblastoma and the search for a cure: where do

- we stand? *Cell Mol Life Sci* 74(13): 2451-2466, 2017. PMID: 28210785. DOI: 10.1007/s00018-017-2483-3
- 6 Yan D, Sherman JH and Keidar M: Cold atmospheric plasma, a novel promising anti-cancer treatment modality. *Oncotarget* 8(9): 15977-15995, 2017. PMID: 27845910. DOI: 10.18632/oncotarget.13304
  - 7 Weltmann KD, Kindel E, Woedtke T, Hähnel M, Stieber M and Brandenburg R: Atmospheric pressure plasma sources: prospective tools for plasma medicine. *Pure Appl Chem* 82: 1223-1237, 2010. DOI: 10.1351/PAC-CON-09-10-35
  - 8 Woedtke T, Emmert S, Metelmann HR, Rupf S and Weltmann KD: Perspectives on cold atmospheric plasma (CAP) applications in medicine. *Phys Plasmas* 27: 70601, 2020. DOI: 10.1063/5.0008093
  - 9 Semmler ML, Bekeschus S, Schäfer M, Bernhardt T, Fischer T, Witzke K, Seebauer C, Rebl H, Grambow E, Vollmar B, Nebe JB, Metelmann HR, Woedtke TV, Emmert S and Boeckmann L: Molecular mechanisms of the efficacy of cold atmospheric pressure plasma (CAP) in cancer treatment. *Cancers (Basel)* 12(2): 269, 2020. PMID: 31979114. DOI: 10.3390/cancers12020269
  - 10 Haertel B, von Woedtke T, Weltmann KD and Lindequist U: Non-thermal atmospheric-pressure plasma possible application in wound healing. *Biomol Ther (Seoul)* 22(6): 477-490, 2014. PMID: 25489414. DOI: 10.4062/biomolther.2014.105
  - 11 Stope MB: Plasma oncology – physical plasma as innovative tumor therapy. *J Cancer Biol* 1: 53-56, 2020. DOI: 10.46439/cancerbiology.1.010
  - 12 Reuter S, Woedtke T and Weltmann KD: The Kinpen—a review on physics and chemistry of the atmospheric pressure plasma jet and its applications. *J Phys D Appl Phys* 51: 233001, 2018. DOI: 10.1088/1361-6463/aab3ad
  - 13 McDowell KA, Riggins GJ and Gallia GL: Targeting the AKT pathway in glioblastoma. *Curr Pharm Des* 17(23): 2411-2420, 2011. PMID: 21827416. DOI: 10.2174/138161211797249224
  - 14 Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev* 68(2): 320-344, 2004. PMID: 15187187. DOI: 10.1128/MMBR.68.2.320-344.2004
  - 15 van Ommeren R, Staudt MD, Xu H and Hebb MO: Advances in HSP27 and HSP90-targeting strategies for glioblastoma. *J Neurooncol* 127(2): 209-219, 2016. PMID: 26842818. DOI: 10.1007/s11060-016-2070-8
  - 16 Laroussi M: Cold plasma in medicine and healthcare: The new frontier in low temperature plasma applications. *Frontiers in Physics* 8, 2020. DOI: 10.3389/fphy.2020.00074
  - 17 Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R and Trink B: Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. *Br J Cancer* 105(9): 1295-1301, 2011. PMID: 21979421. DOI: 10.1038/bjc.2011.386
  - 18 Partecke LI, Evert K, Haugk J, Doering F, Normann L, Diedrich S, Weiss FU, Evert M, Huebner NO, Guenther C, Heidecke CD, Kramer A, Bussiahn R, Weltmann KD, Pati O, Bender C and von Bernstorff W: Tissue tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells *in vitro* and *in vivo*. *BMC Cancer* 12: 473, 2012. PMID: 23066891. DOI: 10.1186/1471-2407-12-473
  - 19 Vaquero J, Judée F, Vallette M, Decauchy H, Arbelaz A, Aoudjehane L, Scatton O, Gonzalez-Sanchez E, Merabtene F, Augustin J, Housset C, Dufour T and Fouassier L: Cold atmospheric plasma induces tumor cell death in preclinical *in vivo* and *in vitro* models of human cholangiocarcinoma. *Cancers (Basel)* 12(5): 1280, 2020. PMID: 32438553. DOI: 10.3390/cancers12051280
  - 20 Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Ishikawa K, Kondo H, Kano H, Hori M and Kikkawa F: Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells *in vitro* and *in vivo*. *PLoS One* 8(12): e81576, 2013. PMID: 24367486. DOI: 10.1371/journal.pone.0081576
  - 21 Alimohammadi M, Golpur M, Sohbatzadeh F, Hadavi S, Bekeschus S, Niaki HA, Valadan R and Rafiei A: Cold atmospheric plasma is a potent tool to improve chemotherapy in melanoma *in vitro* and *in vivo*. *Biomolecules* 10(7): 1011, 2020. PMID: 32650505. DOI: 10.3390/biom10071011
  - 22 Koensgen D, Besic I, Gümbel D, Kaul A, Weiss M, Diesing K, Kramer A, Bekeschus S, Mustea A and Stope MB: Cold atmospheric plasma (CAP) and CAP-stimulated cell culture media suppress ovarian cancer cell growth - a putative treatment option in ovarian cancer therapy. *Anticancer Res* 37(12): 6739-6744, 2017. PMID: 29187451. DOI: 10.21873/anticancer.12133
  - 23 Privat-Maldonado A, Gorbanev Y, Dewilde S, Smits E and Bogaerts A: Reduction of human glioblastoma spheroids using cold atmospheric plasma: the combined effect of short- and long-lived reactive species. *Cancers (Basel)* 10(11): 394, 2018. PMID: 30360539. DOI: 10.3390/cancers10110394
  - 24 Cheng X, Sherman J, Murphy W, Ratovitski E, Canady J and Keidar M: The effect of tuning cold plasma composition on glioblastoma cell viability. *PLoS One* 9(5): e98652, 2014. PMID: 24878760. DOI: 10.1371/journal.pone.0098652
  - 25 Daeschlein G, Hillmann A, Gümbel D, Sicher C, von Podewils S, Stope MB and Jünger M: Enhanced anticancer efficacy by drug chemotherapy and cold atmospheric plasma against melanoma and glioblastoma cell lines *in vitro*. *IEEE Transact Radiation Plasma Med Sci* 2: 153-159, 2018. DOI: 10.1109/TRPMS.2018.2789659
  - 26 Chen Z, Simonyan H, Cheng X, Gjika E, Lin L, Canady J, Sherman JH, Young C and Keidar M: A novel micro cold atmospheric plasma device for glioblastoma both *in vitro* and *in vivo*. *Cancers (Basel)* 9(6): 61, 2017. PMID: 28555065. DOI: 10.3390/cancers9060061
  - 27 Köritzer J, Boxhammer V, Schäfer A, Shimizu T, Klämpfl TG, Li YF, Welz C, Schwenk-Zieger S, Morfill GE, Zimmermann JL and Schlegel J: Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. *PLoS One* 8(5): e64498, 2013. PMID: 23704990. DOI: 10.1371/journal.pone.0064498
  - 28 Gjika E, Pal-Ghosh S, Kirschner ME, Lin L, Sherman JH, Stepp MA and Keidar M: Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. *Sci Rep* 10(1): 16495, 2020. PMID: 33020527. DOI: 10.1038/s41598-020-73457-7
  - 29 Bekeschus S, Ispirjan M, Freund E, Kinnen F, Moritz J, Saadati F, Eckroth J, Singer D, Stope MB, Wende K, Ritter CA, Schroeder HWS and Marx S: Gas plasma exposure of glioblastoma is cytotoxic and immunomodulatory in patient-derived GBM tissue. *Cancers (Basel)* 14(3): 813, 2022. PMID: 35159079. DOI: 10.3390/cancers14030813
  - 30 Chautard E, Ouédraogo ZG, Biau J and Verrelle P: Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. *J Neurooncol* 117(2): 205-215, 2014. PMID: 24477623. DOI: 10.1007/s11060-014-1382-9

- 31 Manning BD and Toker A: AKT/PKB signaling: navigating the network. *Cell* 169(3): 381-405, 2017. PMID: 28431241. DOI: 10.1016/j.cell.2017.04.001
- 32 Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 273(22): 13375-13378, 1998. PMID: 9593664. DOI: 10.1074/jbc.273.22.13375
- 33 Zinda MJ, Vlahos CJ and Lai MT: Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. *Biochem Biophys Res Commun* 280(4): 1107-1115, 2001. PMID: 11162641. DOI: 10.1006/bbrc.2000.4248
- 34 Koundouros N and Pouligiannis G: Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. *Front Oncol* 8: 160, 2018. PMID: 29868481. DOI: 10.3389/fonc.2018.00160
- 35 Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB and Dedhar S: Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. *Oncogene* 24(22): 3596-3605, 2005. PMID: 15782140. DOI: 10.1038/sj.onc.1208427
- 36 Kim SJ, Jung HJ and Lim CJ: Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress. *Biochem Genet* 51(11-12): 901-915, 2013. PMID: 23832602. DOI: 10.1007/s10528-013-9616-7
- 37 Wen C, Wang H, Wu X, He L, Zhou Q, Wang F, Chen S, Huang L, Chen J, Wang H, Ye W, Li W, Yang X, Liu H and Peng J: ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antitumor effects of thioredoxin reductase-1 inhibitor chaetocin. *Cell Death Dis* 10(11): 809, 2019. PMID: 31649256. DOI: 10.1038/s41419-019-2035-x
- 38 Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J, Roldan P, Gonzalez-Darder J and Cerdá-Nicolás M: The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. *Neuropathology* 28(5): 507-515, 2008. PMID: 18410277. DOI: 10.1111/j.1440-1789.2008.00911.x
- 39 Zimmermann T, Gebhardt LA, Kreiss L, Schneider C, Arndt S, Karrer S, Friedrich O, Fischer MJM and Bosserhoff AK: Acidified nitrite contributes to the antitumor effect of cold atmospheric plasma on melanoma cells. *Int J Mol Sci* 22(7): 3757, 2021. PMID: 33916572. DOI: 10.3390/ijms22073757
- 40 Nakai N, Fujita R, Kawano F, Takahashi K, Ohira T, Shibaguchi T, Nakata K and Ohira Y: Retardation of C2C12 myoblast cell proliferation by exposure to low-temperature atmospheric plasma. *J Physiol Sci* 64(5): 365-375, 2014. PMID: 25034108. DOI: 10.1007/s12576-014-0328-5
- 41 Arndt S, Wacker E, Li YF, Shimizu T, Thomas HM, Morfill GE, Karrer S, Zimmermann JL and Bosserhoff AK: Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells. *Exp Dermatol* 22(4): 284-289, 2013. PMID: 23528215. DOI: 10.1111/exd.12127
- 42 Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev* 22(2): 153-183, 2001. PMID: 11294822. DOI: 10.1210/edrv.22.2.0428
- 43 McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta* 1773(8): 1263-1284, 2007. PMID: 17126425. DOI: 10.1016/j.bbamcr.2006.10.001
- 44 Chetram MA and Hinton CV: PTEN regulation of ERK1/2 signaling in cancer. *J Recept Signal Transduct Res* 32(4): 190-195, 2012. PMID: 22737980. DOI: 10.3109/10799893.2012.695798
- 45 Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. *Nat Rev Cancer* 5(10): 761-772, 2005. PMID: 16175177. DOI: 10.1038/nrc1716
- 46 Siegelin MD, Plescia J, Raskett CM, Gilbert CA, Ross AH and Altieri DC: Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. *Mol Cancer Ther* 9(6): 1638-1646, 2010. PMID: 20501802. DOI: 10.1158/1535-7163.MCT-10-0097
- 47 Li J and Buchner J: Structure, function and regulation of the hsp90 machinery. *Biomed J* 36(3): 106-117, 2013. PMID: 23806880. DOI: 10.4103/2319-4170.113230
- 48 Stope MB, Koensgen D, Burchardt M, Concin N, Zygmunt M and Mustea A: Jump in the fire—heat shock proteins and their impact on ovarian cancer therapy. *Crit Rev Oncol Hematol* 97: 152-156, 2016. PMID: 26318096. DOI: 10.1016/j.critrevonc.2015.08.008
- 49 Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R and Weller M: Expression and functional activity of heat shock proteins in human glioblastoma multiforme. *Neurology* 54(6): 1357-1365, 2000. PMID: 10746610. DOI: 10.1212/wnl.54.6.1357
- 50 Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW and Wen PY: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. *Neuro Oncol* 11(2): 109-121, 2009. PMID: 18682579. DOI: 10.1215/15228517-2008-060
- 51 Chen H, Gong Y, Ma Y, Thompson RC, Wang J, Cheng Z and Xue L: A brain-penetrating Hsp90 inhibitor NXD30001 inhibits glioblastoma as a monotherapy or in combination with radiation. *Front Pharmacol* 11: 974, 2020. PMID: 32695001. DOI: 10.3389/fphar.2020.00974
- 52 Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, Feron O and Calderon PB: Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. *Biochem Pharmacol* 77(3): 375-383, 2009. PMID: 19014912. DOI: 10.1016/j.bcp.2008.10.019
- 53 Bekeschus S, Lippert M, Diepold K, Chiosis G, Seufferlein T and Azoitei N: Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone. *Sci Rep* 9(1): 4112, 2019. PMID: 30858416. DOI: 10.1038/s41598-019-38580-0
- 54 Weiss M, Gumbel D, Hanschmann EM, Mandelkow R, Gelbrich N, Zimmermann U, Walther R, Ekkernkamp A, Sckell A, Kramer A, Burchardt M, Lillig CH and Stope MB: Cold atmospheric plasma treatment induces anti-proliferative effects in prostate cancer cells by redox and apoptotic signaling pathways. *PLoS One* 10(7): e0130350, 2015. PMID: 26132846. DOI: 10.1371/journal.pone.0130350
- 55 Feil L, Koch A, Utz R, Ackermann M, Barz J, Stope M, Krämer B, Wallwiener D, Brucker SY and Weiss M: Cancer-selective treatment of cancerous and non-cancerous human cervical cell

- models by a non-thermally operated electrosurgical argon plasma device. *Cancers (Basel)* 12(4): 1037, 2020. PMID: 32340164. DOI: 10.3390/cancers12041037
- 56 Jung YS, Qian Y and Chen X: Examination of the expanding pathways for the regulation of p21 expression and activity. *Cell Signal* 22(7): 1003-1012, 2010. PMID: 20100570. DOI: 10.1016/j.cellsig.2010.01.013
- 57 Moldovan GL, Pfander B and Jentsch S: PCNA, the maestro of the replication fork. *Cell* 129(4): 665-679, 2007. PMID: 17512402. DOI: 10.1016/j.cell.2007.05.003
- 58 Schneider C, Arndt S, Zimmermann JL, Li Y, Karrer S and Bosserhoff AK: Cold atmospheric plasma treatment inhibits growth in colorectal cancer cells. *Biol Chem* 400(1): 111-122, 2018. PMID: 29908123. DOI: 10.1515/hsz-2018-0193
- 59 Eggers B, Stope MB, Marciniak J, Götz W, Mustea A, Deschner J, Nokhbehsaim M and Kramer FJ: Non-invasive physical plasma generated by a medical argon plasma device induces the expression of regenerative factors in human gingival keratinocytes, fibroblasts, and tissue biopsies. *Biomedicines* 10(4): 889, 2022. PMID: 35453639. DOI: 10.3390/biomedicines10040889
- 60 Eggers B, Marciniak J, Memmert S, Kramer FJ, Deschner J and Nokhbehsaim M: The beneficial effect of cold atmospheric plasma on parameters of molecules and cell function involved in wound healing in human osteoblast-like cells *in vitro*. *Odontology* 108(4): 607-616, 2020. PMID: 32030565. DOI: 10.1007/s10266-020-00487-y
- 61 Kordt M, Trautmann I, Schlie C, Lindner T, Stenzel J, Schildt A, Boeckmann L, Bekeschus S, Kurth J, Krause BJ, Vollmar B and Grambow E: Multimodal imaging techniques to evaluate the anticancer effect of cold atmospheric pressure plasma. *Cancers (Basel)* 13(10): 2483, 2021. PMID: 34069689. DOI: 10.3390/cancers13102483
- 62 Han C, Shen JK, Hornicek FJ, Kan Q and Duan Z: Regulation of microRNA-1 (miR-1) expression in human cancer. *Biochim Biophys Acta Gene Regul Mech* 1860(2): 227-232, 2017. PMID: 27923712. DOI: 10.1016/j.bbagr.2016.12.004
- 63 Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari K, Ogawa D, Balaj L, De Rienzo G, Mineo M, Nakano I, Ostrowski MC, Hochberg F, Weissleder R, Lawler SE, Chiocca EA and Godlewski J: Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. *Cancer Res* 74(3): 738-750, 2014. PMID: 24310399. DOI: 10.1158/0008-5472.CAN-13-2650
- 64 Weiss M, Brandenburg LO, Burchardt M and Stope MB: MicroRNA-1 properties in cancer regulatory networks and tumor biology. *Crit Rev Oncol Hematol* 104: 71-77, 2016. PMID: 27286699. DOI: 10.1016/j.critrevonc.2016.05.014
- 65 Soni V, Adhikari M, Simonyan H, Lin L, Sherman JH, Young CN and Keidar M: *In vitro* and *in vivo* enhancement of temozolomide effect in human glioblastoma by non-invasive application of cold atmospheric plasma. *Cancers (Basel)* 13(17): 4485, 2021. PMID: 34503293. DOI: 10.3390/cancers13174485

Received October 8, 2022

Revised November 10, 2022

Accepted November 14, 2022